Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2007, Vol. 5 ›› Issue (3): 263-267.doi: 10.3736/jcim20070307

• Original Clinical Research • Previous Articles     Next Articles

Clinical research of Yiqi Sanju Formula in treating central obese men at high risk of metabolic syndrome

Chun-yan He1, Wen-jian Wang1, Bin Li2, De-sheng Xu1, Wei-hua Chen1, Jiang Ying1, Yan-ming He1   

  1. 1. Institute of Chinese Integrative Medicine, Fudan University, Shanghai 200040, China
    2. Department of Internal Medicine, Fengcheng People's Hospital, Fengxian District, Shanghai 201411, China
  • Online:2007-05-31 Published:2007-05-15

Objective: To observe the therapeutic effects of Yiqi Sanju Formula (YQSJF), a compound Chinese herbal medicine, on central obese men at high risk of metabolic syndrome (MS).

Methods: Compared with 30 healthy male volunteers, 45 central obese men were separated randomly into two groups and received the interventions with YQSJF and placebo respectively for 10 weeks. Baseline characteristics, insulin resistance, inflammation cytokines and plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) were evaluated before and after treatment. 

Result: The score of homeostatic model assessment for insulin resistance (HOMA-IR) and the levels of C reactive protein (CRP), free fatty acid (FFA) and PAI-1 in obese men were higher than those in the control group, while t-PA was lower. After treatment, compared with placebo group, body mass index, waist, and waist-to-hip ratio were decreased significantly in subjects who received YQSJF (P<0.01). The score of HOMA-IR and the levels of CRP, FFA and PAI-1 were decreased significantly, and the level of t-PA was increased significantly (P<0.01). 

Conclusion: YQSJF can reduce obesity and insulin resistance in central obese men at high risk of MS and improve inflammation and fibrinolysis, which indicates that it can reduce the risk of atherosclerosis.

Key words: metabolic syndrome, obesity, insulin, traditional Chinese medicine

CLC Number: 

  • R589

Table 1

Common state before and after treatment (ヌ±S)"

GroupnAge (year)BMI (kg/m2)Waist (cm)WHR
Before treatment2246.04±5.7627.50±2.22**96.26±5.93**0.93±0.04**
After treatment2246.04±5.7626.70±2.81△△▲▲92.74±5.30△△▲▲0.91±0.02△△▲▲
Before treatment2345.68±6.3926.98±2.81**97.41±6.73**0.94±0.03**
After treatment2345.68±6.3927.00±2.8496.69±6.730.94±0.04

Table 2

Changes of FBG, TG and HOMA-IR before and after treatment (ヌ±S)"

GroupnFBG (mmol/L)TG (mmol/L)HOMA-IR
Before treatment225.03±0.391.30±0.332.68±0.85**
After treatment225.16±0.361.39±0.411.76±0.64△△▲▲
Before treatment235.09±0.341.26±0.332.66±0.92**
After treatment235.27±0.441.36±0.422.89±1.41

Table 3

Changes of CRP, FFA, PAI-1 and t-PA before and after treatment (ヌ±S)"

GroupnCRP (mg/L)FFA (mmol/L)PAI-1 (μg/L)t-PA (μg/L)
Before treatment224.79±2.69*0.65±0.33**35.28±11.52**16.26±4.89*
After treatment222.89±1.40△△▲▲0.42±0.20△△▲22.74±5.30△▲24.14±8.85△△▲▲
Before treatment235.18±3.70*0.65±0.27**31.01±10.09*14.27±6.23**
After treatment235.48±2.660.61±0.2231.05±10.2414.01±6.80
[1] 顾东风, Reynolds K, 杨文杰, 等.中国成年人代谢综合征的患病率.中国糖尿病杂志,2005,13(3):181-185
Gu DF, Reynolds K, Yang WJ, et al.The prevalence of metabolic syndrome in the general adult population aged 35-74 years in China.Zhongguo Tang Niao Bing Za Zhi,2005,13(3):181-185
[2] Temelkova-Kurktschiev T, Siegert G, Bergmann S, et al.Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes.Metabolism,2002,51(6):743-749
[3] Florez H, Castillo-Florez S, Mendez A, et al.C-reactive protein is elevated in obese patients with the metabolic syndrome.Diabetes Res Clin,2006,71(1):92-100
doi: 10.1016/j.diabres.2005.05.003 pmid: 16002176
[4] Bastard JP, Maachi M, Lagathu C, et al.Recent advances in the relationship between obesity, inflammation, and insulin resistance.Eur Cytokine Netw,2006,17(1):4-12
doi: 10.1104/pp.92.4.891 pmid: 16613757
[5] Mertens I, Ballaux D, Funahashi T, et al.Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.Thromb Haemost,2005,94(6):1190-1195
[6] Alessi MC, Juhan-Vague I.PAI-1 and the metabolic syndrome: links, causes, and consequences.Arterioscler Thromb Vasc Biol,2006,26(10):2200-2207
doi: 10.1161/01.ATV.0000242905.41404.68 pmid: 16931789
[7] 王文健. 聚证学说的建立和应用.中西医结合学报,2007,5(2):111-114
Wang WJ.Foundation and application of aggregation theory in traditional Chinese medicine.Zhong Xi Yi Jie He Xue Bao,2007,5(2):111-114
[8] 王树海, 王文健, 汪雪峰, 等.黄芪多糖和小檗碱对3T3-L1脂肪细胞糖代谢及细胞分化的影响.中国中西医结合杂志,2004,24(10):926-928
Wang SH, Wang WJ, Wang XF, et al.Effect of astragalus polysaccharides and berberine on carbohydrate metabolism and cell differentiation in 3T3-L1 adipocytes.Zhongguo Zhong Xi Yi Jie He Za Zhi,2004,24(10):926-928
[9] 何燕铭, 王文健, 陈伟华, 等.蒲黄总黄酮对3T3-L1脂肪细胞糖脂代谢的影响.中西医结合学报,2006,4(6):593-595
He YM, Wang WJ, Chen WH, et al.Effects of Pollen Typhae total flavone on glucose and lipid metabolism in 3T3-L1 adipocytes.Zhong Xi Yi Jie He Xue Bao,2006,4(6):593-595
[10] Kahn SE, Zinman B, Haffner SM, et al.Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.Diabetes Res Clin Pract,2006,71(1):92-100
[11] Kahn SE, Zinman B, Haffner SM, et al.Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.Diabetes,2006,55(8):2357-2364
[12] Bo S, Gambino R, Uberti B, et al.Does C-reactive protein identify a subclinical metabolic disease in healthy subjects.Eur J Clin Invest,2005,35(4):265-270
doi: 10.1111/j.1365-2362.2005.01490.x pmid: 15816996
[13] Boden G.Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver.Curr Diab Rep,2006,6(3):177-181
doi: 10.1007/s11892-006-0031-x pmid: 16898568
[14] Nieuwdorp M, Stroes ES, Meijers JC, et al.Hypercoagulability in the metabolic syndrome.Curr Opin Pharmacol,2005,5(2):155-159
doi: 10.1016/j.coph.2004.10.003 pmid: 15780824
[15] Umpaichitra V, Hussain MM, Castells S.Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.Pediatr Res,2005,58(3):483-487
[1] Wan-jun Guo, Yi Wang, Yu Deng, Lin-yan Cheng, Xin Liu, Ruo-fan Xi, Sheng-jie Zhu, Xin-yi Feng, Liang Hua, Kan Ze, Jian-yong Zhu, Dong-jie Guo, Fu-lun Li. Therapeutic effects of the extract of Sancao Formula, a Chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61. Journal of Integrative Medicine, 2022, 20(4): 376-384.
[2] Shang-jin Song, Xuan Liu, Qing Ji, Da-zhi Sun, Li-juan Xiu, Jing-yu Xu, Xiao-qiang Yue. Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression. Journal of Integrative Medicine, 2022, 20(4): 355-364.
[3] Zeinab Vafaeipour, Bibi Marjan Razavi, Hossein Hosseinzadeh. Effects of turmeric (Curcuma longa) and its constituent (curcumin) on the metabolic syndrome: An updated review. Journal of Integrative Medicine, 2022, 20(3): 193-203.
[4] Marisa Casal. Improving the health and treatment success rates of in vitro fertilization patients with traditional chinese medicine: need for more robust evidence and innovative approaches. Journal of Integrative Medicine, 2022, 20(3): 187-192.
[5] Ning Guo, Fei Wu, Mei Wu, Yuan Wang, Qing Lang, Xiao Lin, Yi Feng. Progress in the design and quality control of placeboes for clinical trials of traditional Chinese medicine . Journal of Integrative Medicine, 2022, 20(3): 204-212.
[6] Yan-jun Lin, Kun-li Jiao, Bo Liu, Lu Fang, Shu Meng. Antiplatelet and myocardial protective effect of shexiang tongxin dropping pill in patients undergoing percutaneous coronary intervention: A randomized controlled trial. Journal of Integrative Medicine, 2022, 20(2): 126-134.
[7] Jia-jia Li, Qing Liang, Guang-chun Sun. Traditional Chinese medicine for prevention and treatment of hepatocellular carcinoma: A focus on epithelial-mesenchymal transition. Journal of Integrative Medicine, 2021, 19(6): 469-477.
[8] Rui-jin Qiu, Min Li, Jia-yuan Hu, Jing Chen, Hong-cai Shang. Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine. Journal of Integrative Medicine, 2021, 19(5): 389-394.
[9] Mao-xing Pan, Chui-yang Zheng, Yuan-jun Deng, Kai-rui Tang, Huan Nie, Ji-qian Xie, Dong-dong Liu, Gui-fang Tu, Qin-he Yang, Yu-pei Zhang. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease . Journal of Integrative Medicine, 2021, 19(5): 428-438.
[10] Ning Zhang, Xiao-he Xiao. Integrative medicine in the era of cancer immunotherapy: Challenges and opportunities. Journal of Integrative Medicine, 2021, 19(4): 291-294.
[11] Thomas Efferth, An-long Xu, Roxana Damiescu, Mita Banerjee, Norbert W. Paul, David Y.W. Lee. Can eastern wisdom resolve western epidemics? Traditional chinese medicine therapies and the opioid crisis. Journal of Integrative Medicine, 2021, 19(4): 295-299.
[12] Si-qi Tang, Yun-liang Wang, Zi-ye Xie, Yang Zhang, Yi Guo, Kang-li Gao, Tang-you Mao, Chun-e Xie, Jun-xiang Li, Xiao-yan Gao. Serum metabolic profiling of traditional Chinese medicine syndromes in patients with diarrhea-predominant irritable bowel syndrome. Journal of Integrative Medicine, 2021, 19(3): 274-281.
[13] Miao-yan Shi, Shi-qi Sun, Wei Zhang, Xing Zhang, Gui-hua Xu, Xuan Chen, Zi-jian Su, Xiu-ming Song, Lu-jiong Liu, Yi-bao Zhang, Yi-le Zhang, Meng Sun, Qi Chen, Yan Xue, Hua Lü, Wei-an Yuan, Xiao-rong Chen, Yun-fei Lu. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: a retrospective cohort study. Journal of Integrative Medicine, 2021, 19(3): 226-231.
[14] Shu-jun Wei, Qing-man He, Qing Zhang, Kang-hua Fu, Ruo-lan Li, Wei Peng, Yong-xiang Gao. Traditional Chinese medicine is a useful and promising alternative strategy for treatment of Sjogren's syndrome: A review. Journal of Integrative Medicine, 2021, 19(3): 191-202.
[15] Yi Xia, Lu-shao-bo Shi, Jing-hui Chang, Hua-zhang Miao, Dong Wang. Impact of the COVID-19 pandemic on intention to use traditional Chinese medicine: A cross-sectional study based on the theory of planned behavior. Journal of Integrative Medicine, 2021, 19(3): 219-225.
Full text



[1] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. An explanation on "guiding principles of clinical research on mild cognitive impairment (protocol)". Journal of Chinese Integrative Medicine, 2008, 6(1): 15-21
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[4] Wei Zhang, Xiang-feng Lu, Xiao-mei Zhang, Jian-jun Wu, Liang-duo Jiang. A rat model of pulmonary fibrosis induced by infusing bleomycin quickly through tracheal intubation. Journal of Chinese Integrative Medicine, 2008, 6(1): 60-67
[5] A-gao Zhou, Yong Zhang, Gang Kui, De-Yun Kong, Hai-liang Ge, Qiu-hua Ren, Jia-rong Dong, Sheng Hong, Xu-ming Mao, Yin Wang, Hui-zheng Zhang, Shu-jun Wang. Influence of traditional Chinese compound recipes with different efficacy on body weight, tumor weight and immune function in H22 cancer-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 77-82
[6] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[7] Li Zhou, Hong-xing Zhang, Ling-guang Liu, Wen-jun Wan. Effect of electro-acupuncture at Fenglong (GV 16) on nitric oxide and endothelin in rats with hyperlipidemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 89-92
[8] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[9] Xin-jun Wang, Ling-ling Wang . A mechanism of endogenous opioid peptides for rapid onset of acupuncture effect in treatment of depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1014-1017
[10] Bo Wang , Wei Yan , Li-hui Hou, Xiao-ke Wu. Disorder of Tiangui (kidney essence) and reproductive dysfunction in patients with polycystic ovary syndrome. Journal of Chinese Integrative Medicine, 2010, 8(11): 1018-1022